연구동향 분석

Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite

김세형 김도훈 변지영 김영훈 김동현 임혜진 이충민 Sang Sup Whang 최창익 배정우 이윤정 장춘곤 이석용 2017년

논문상세정보
인용/피인용

' Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite' 의 참고문헌

  • Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports
    Moore RA Arthritis Res Ther 7 R644-R665 [2005]
  • Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans
    Lee CR J Clin Pharmacol 43 84-91 [2003]
  • Substrate-dependent functional alterations of seven CYP2C9 variants found in Japanese subjects
    Maekawa K Drug Metab Dispos 37 1895-1903 [2009]
  • Strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals
    Lee HI Pharmacogenet Genom 24 113-117 [2014]
  • Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans
    Guo Y Drug Metab Dispos 33 749-753 [2005]
  • Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis
    Caldwell B J R Soc Med 99 132-140 [2006]
  • Power and sample size calculations for studies involving linear regression
    Dupont WD Control Clin Trials 19 589-601 [1998]
  • Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans
    Kirchheiner J Br J Clin Pharmacol 55 51-61 [2003]
  • Oxidation of celecoxib by polymorphic cytochrome P450 2C9and alcohol dehydrogenase
    Sandberg M Br J Clin Pharmacol 54 423-429 [2002]
  • On the human CYP2C9*13 variant activity reduction: a molecular dynamics simulation and docking study
    Zhou YH Biochimie 88 1457-1465 [2006]
  • Metabolism and excretion of [14C]celecoxib in healthy male volunteers
    Paulson SK Drug Metab Dispos 28 308-314 [2000]
  • Major role of human liver microsomal cytochrome P450 2C9(CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor
    Tang C J Pharmacol Exp Ther 293 453-459 [2000]
  • Lornoxicam pharmacokinetics in relation to cytochrome P4502C9 genotype
    Zhang Y Br J Clin Pharmacol 59 14-17 [2005]
  • Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration?
    Martin JH Br J Clin Pharmacol 51 627-630 [2001]
  • Interethnic and intraethnic variability of CYP2C8 and CYP2C9polymorphisms in healthy individuals
    Garcı´a-Martı´n E Mol Diagn Ther 10 29-40 [2006]
  • Integrated cytochrome P450 reaction phenotyping:attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes
    Rodrigues AD Biochem Pharmacol 57 465-480 [1999]
  • Influence of genetic polymorphisms on the pharmacokinetics of celecoxib and its two main metabolites in healthy Chinese subjects
    Liu R Eur J Pharm Sci 79 13-19 [2015]
  • Influence of age and cytochrome P450 2C9genotype on the steady-state disposition of diclofenac and celecoxib
    Brenner SS Clin Pharmacokinet 42 283-292 [2003]
  • Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam
    Perini JA Clin Pharmacol Ther 78 362-369 [2005]
  • Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites
    Kirchheiner J Pharmacogenetics 13 473-480 [2003]
  • Identification of a novel variant CYP2C9 allele in Chinese
    Si D Pharmacogenetics 14 465-469 [2004]
  • Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use
    Martinez C Br J Pharmacol 141 205-208 [2004]
  • Gastropathy due to celecoxib, a cyclooxygenase-2 inhibitor
    Mohammed S N Engl J Med 340 2005-2006 [1999]
  • Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics
    Bae JW Acta Pharmacol Sin 32 1303-1308 [2011]
  • Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib
    Prieto-Pe´rez R J Clin Pharmacol 53 1261-1267 [2013]
  • Ethnic differences in CYP2C9*2(Arg144Cys) and CYP2C9*3 (Ile359Leu) genotypes in Japanese and Israeli populations
    Nakai K Life Sci 78 107-111 [2005]
  • Effects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites
    변지영 Archives of Pharmacal Research 38 11 2083-2091 [2015]
  • Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects
    Li Z Xenobiotica 39 788-793 [2009]
  • Effects of the CYP2C9*1/*13 genotype on the pharmacokinetics of lornoxicam
    Choi CI Basic Clin Pharmacol Toxicol 109 476-480 [2011]
  • Effects of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjects
    이윤정 Archives of Pharmacal Research 38 6 1232-1237 [2015]
  • Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174
    Bae JW Int J Clin Pharmacol Ther 50 683-689 [2012]
  • Effects of CYP2C9*1/*13 on the pharmacokinetics and pharmacodynamics of meloxicam
    Bae JW Br J Clin Pharmacol 71 550-555 [2011]
  • Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of zafirlukast
    이현지 Archives of Pharmacal Research 39 7 1013-1019 [2016]
  • Effect of the CYP2C9*3 allele on lornoxicam metabolism
    Liu YL Clin Chim Acta 364 287-291 [2006]
  • Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes
    Lee CR Eur J Clin Pharmacol 58 791-794 [2003]
  • Cytochrome P4502C9: an enzyme of major importance in human drug metabolism
    Miners JO Br J Clin Pharmacol 51 1003-1008 [1998]
  • Cytochrome P450 2C9polymorphisms: a comprehensive review of the in vitro and human data
    Lee CR Pharmacogenetics 12 251-263 [2002]
  • Cytochrome P450 2C9 genotype: impact on celecoxib safety and pharmacokinetics in a pediatric patient
    Stempak D Clin Pharmacol Ther 78 309-310 [2005]
  • Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups
    Scott SA Pharmacogenomics 11 781-791 [2011]
  • Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor
    Davies NM Clin Pharmacokinet 38 225-242 [2000]
  • Clinical consequences of cytochrome P450 2C9 polymorphisms
    Kirchheiner J Clin Pharmacol Ther 77 1-16 [2005]
  • Catalytic activities of human cytochrome P450 2C9*1, 2C9*3and 2C9*13
    Guo Y Xenobiotica 35 853-861 [2005]
  • CYP2C9*3 and *13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects
    Choi CI Eur J Clin Pharmacol 68 149-154 [2012]
  • CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians
    Vienna-Jorge R Clin Pharmacol Ther 76 18-26 [2004]
  • Are altered pharmacokinetics of nonsteroidal anti-inflammatory drugs (NSAIDs) a risk factor for gastrointestinal bleeding?
    Wynne HA Br J Clin Pharmacol 45 405-408 [1998]
  • Allele and genotype frequencies of CYP2C9 in a Korean population
    Bae JW Br J Clin Pharmacol 60 418-422 [2005]
  • Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for CYP2C9*3
    Lundbald MS Clin Pharmacol Ther 79 287-288 [2006]